Side-effect concerns dampen AZ/Ardelyx's first-in-class drug promise
This article was originally published in Scrip
A Phase IIb study of Ardelyx's selective NHE3 inhibitor tempanor has thrown up a side-effect concern in one of its potential indications, hyperphosphatemia. Shares in the firm dropped by 29% to close at $19.25 on Nasdaq on 2 February.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.